OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma
NCT07739017
·
clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
54
Enrollment
OTHER
Sponsor class
Conditions
Recurrent Glioblastoma
Newly Diagnosed MGMT Unmethylated Glioblastoma
Interventions
DRUG:
CT-179
Sponsor
Olivia Newton-John Cancer Research Institute
Collaborators
[object Object]